Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine. Paris, France 2 May 2022 – Orphalan…
adminMay 2, 2022
Paris, France 1 February 2022 – Orphalan SA, a Company that identifies, develops, and delivers therapies worldwide for orphan diseases, today announces two new appointments to the management team. Tim…
Minesh KothariFebruary 1, 2022
Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease —NDA supported by positive data from Phase 3…
adminSeptember 2, 2021
JUNE 25, 2021 - ORPHAN DISEASES — CHELATE trial confirmed trientine tetrahydrochloride was non-inferior to d-Penicillamine and met the primary endpoint of Non-Ceruloplasmin Copper (NCC) levels as a maintenance therapy…
adminJune 25, 2021
